Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Florencia Veigas"'
Autor:
Elmer A Fernández, Joaquin P Merlo, Yamil D Mahmoud, Florencia Veigas, Marco A Scheidegger, Alejandro J Cagnoni, Gabriel A Rabinovich, Karina V Marino
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5ba236a9fa294710bd8e4a4e6f29d5e1
Autor:
Martin Moya, Marcela Marrama, Carina Dorazio, Florencia Veigas, Montana N. Manselle Cocco, Tomas Dalotto Moreno, Gabriel A. Rabinovich, Ariel Aleksandroff
Publikováno v:
Vaccines, Vol 10, Iss 6, p 937 (2022)
Background: In spite of compelling evidence demonstrating safety and immunogenicity of adenoviral-based SARS-CoV-2 vaccines in the general population, its effects in socially vulnerable elderly individuals are poorly understood. Here we aimed to inve
Externí odkaz:
https://doaj.org/article/ee2fce83f8a7472ca3f7ad5b5e633712
Autor:
Florencia Veigas, Yamil Damian Mahmoud, Joaquin P. Merlo, Montana Manselle Cocco, Mora Massaro, Sabrina Gatto, Rosa Morales, Maria R. Girotti, Juan M. Perez-Saez, Gabriel A. Rabinovich
Publikováno v:
Cancer Research. 83:2261-2261
Both targeted therapies (TT) and immunotherapies have revolutionized the treatment of metastatic melanoma patients. Particularly, TT with BRAFi or BRAFi/MEKi leads to prompt but not durable responses in most patients due to the development of resista
Autor:
Yamil D. Mahmoud, Natalia Rego, Marcela Vilarino, Florencia Veigas, Maria R. Girotti, Juan M. Perez Saez, Gabriel A. Rabinovich, Marcelo Hill
Publikováno v:
Cancer Research. 83:6548-6548
Although the development of single-cell RNAseq (scRNAseq) has improved the knowledge of the tumor microenvironment (TME), there is not a clear understanding of specific cell subtypes, markers that define these cell populations, nor the interaction be
Autor:
Lorena Laporte, Mora Massaro, Joaquín Pedro Merlo, Montana N Manselle Cocco, Gabriel A. Rabinovich, Nicolas Sarbia, Florencia Veigas, Yamil Damián Mahmoud, Ramiro Martin Perrotta, Anabela M. Cutine, Camila Agustina Bach
Publikováno v:
Science Reviews - from the end of the world. 2:42-63
Endogenous lectins play key roles in cell homeostasis by decoding the information encrypted in glycans present on the cell surface or extracellular matrix. Galectins, a family of soluble lectins, have emerged as central regulators of innate and adapt
Autor:
Florencia Veigas, Yamil Damián Mahmoud, Maria Romina Girotti, Gabriel A. Rabinovich, Adriana Raquel Rinflerch, Joaquín Pedro Merlo
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1018, p 1018 (2021)
Cancers, Vol 13, Iss 1018, p 1018 (2021)
Simple Summary During the last decades, scientific advances in immuno-oncology and a better understanding of tumors’ immune profile led to the development of novel immunotherapeutic strategies, especially immune checkpoint inhibitors. The blockade
Autor:
Matías Miranda, María Romina Girotti, Mónica Balzarini, Elmer Andrés Fernández, Hugo D. Lujan, Gabriel A. Rabinovich, Darío Rocha, Yamil Damián Mahmoud, Florencia Veigas, Joaquín Pedro Merlo
Publikováno v:
Brief Bioinform
The accurate quantification of tumor-infiltrating immune cells turns crucial to uncover their role in tumor immune escape, to determine patient prognosis and to predict response to immune checkpoint blockade. Current state-of-the-art methods that qua
Autor:
Darío Rocha, Gabriel A. Rabinovich, Maria Romina Girotti, Florencia Veigas, Mónica Balzarini, Elmer Andrés Fernández, Joaquín Pedro Merlo, Yamil Damián Mahmoud
Publikováno v:
Web of Science
e15198 Background: Immunotherapies have revolutionized cancer treatment, but responses are not universal and patients who initially respond to therapy develop resistance. The accurate quantification of tumor-infiltrating immune cells holds the promis
Autor:
Florencia Veigas, Yamil D Mahmoud, Ana Flores, Rosa Morales, Sabrina Gatto, Juan Manuel Perez Saez, Elmer Fernandez, Gabriel A Rabinovich, María Romina Girotti
Publikováno v:
The Journal of Immunology. 204:241.41-241.41
Most melanoma patients who develop resistance to targeted therapies do not respond to subsequent immunotherapy. Therefore, establishing which patients would derive clinical benefit from immunotherapy is a compelling clinical question. We performed a
Autor:
Matthieu Rousset, Yamil Damián Mahmoud, Maite Duhalde, Gabriel A. Rabinovich, Mathias Jeldres, Florencia Veigas, R. Andres Floto, Ignacio Anegon, Sofía Russo, Marcelo Hill, Valentina Perez, M. Romina Girotti, Sabina Victoria, Cédric Louvet, Bernard Vanhove, Maria-Cristina Cuturi, Mercedes Segovia, Pierre Charnet
Publikováno v:
Cancer Cell
Cancer Cell, Elsevier, 2019, 35 (5), pp.767-781.e6. ⟨10.1016/j.ccell.2019.04.003⟩
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Cancer Cell, 2019, 35 (5), pp.767-781. ⟨10.1016/j.ccell.2019.04.003⟩
Cancer Cell, Elsevier, 2019, 35 (5), pp.767-781. ⟨10.1016/j.ccell.2019.04.003⟩
Cancer Cell, Elsevier, 2019, 35 (5), pp.767-781.e6. ⟨10.1016/j.ccell.2019.04.003⟩
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Cancer Cell, 2019, 35 (5), pp.767-781. ⟨10.1016/j.ccell.2019.04.003⟩
Cancer Cell, Elsevier, 2019, 35 (5), pp.767-781. ⟨10.1016/j.ccell.2019.04.003⟩
Although immune checkpoint blockers have yielded significant clinical benefits in patients with different malignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane protein 176B (TMEM176B)contribute